Baidu
map

JAMA Oncol:缩短预后不良的癌症患者的ICU留观时间

2015-10-25 zhaoshuang 译 MedSci原创

路透社报道称,一项新研究表明,对于一个预后不良的实体癌瘤患者来说,四天的ICU留观已经足够,血液恶性肿瘤以及一些病势稍轻的患者更适合长时间留观。这些研究结果,结合个人的偏好,将能更好地指导对于病人的临终治疗。研究人员纳入了920例危重癌症患者,比较了有时限的重症监护患者和没时限的重症监护患者30天的全因死亡率和平均生存时间。研究中发现,1-4天的留观时间对于预后不良的实体癌瘤患者已经足够,血液恶性

路透社报道称,一项新研究表明,对于一个预后不良的实体瘤患者来说,四天的ICU留观已经足够,血液恶性肿瘤以及一些病势稍轻的患者更适合长时间留观。


这些研究结果,结合个人的偏好,将能更好地指导对于病人的临终治疗

研究人员纳入了920例危重癌症患者,比较了时间有限的重症监护患者和没时限的重症监护患者30天的全因死亡率和平均生存时间。

研究中发现,1-4天的留观时间对于预后不良的实体癌瘤患者已经足够,血液恶性肿瘤患者以及其他一些病势稍轻的患者则需要留观两周。ICU的SOFA评分与死亡率有重要关联。时间越短,病人感染的机会就越小。长时间的留观不但不能帮助病人,反而会增加病人和家属的痛苦。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=81993, encodeId=642681993e9, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81994, encodeId=268c81994d2, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864718, encodeId=7cbe1864e18fa, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 25 22:10:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289474, encodeId=6d6d12894e436, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488324, encodeId=a38b148832497, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=81993, encodeId=642681993e9, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81994, encodeId=268c81994d2, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864718, encodeId=7cbe1864e18fa, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 25 22:10:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289474, encodeId=6d6d12894e436, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488324, encodeId=a38b148832497, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2016-04-24 忠诚向上

    继续努力

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=81993, encodeId=642681993e9, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81994, encodeId=268c81994d2, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864718, encodeId=7cbe1864e18fa, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 25 22:10:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289474, encodeId=6d6d12894e436, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488324, encodeId=a38b148832497, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
    2015-10-25 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=81993, encodeId=642681993e9, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81994, encodeId=268c81994d2, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864718, encodeId=7cbe1864e18fa, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 25 22:10:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289474, encodeId=6d6d12894e436, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488324, encodeId=a38b148832497, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=81993, encodeId=642681993e9, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=81994, encodeId=268c81994d2, content=继续努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=149, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Apr 24 07:45:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864718, encodeId=7cbe1864e18fa, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Oct 25 22:10:00 CST 2015, time=2015-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289474, encodeId=6d6d12894e436, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488324, encodeId=a38b148832497, content=<a href='/topic/show?id=b34f1001e187' target=_blank style='color:#2F92EE;'>#预后不良#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100171, encryptionId=b34f1001e187, topicName=预后不良)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b86b8414062, createdName=caoliehu, createdTime=Tue Oct 27 11:10:00 CST 2015, time=2015-10-27, status=1, ipAttribution=)]

相关资讯

Cell子刊:癌症研究的八大问题

最近,Cell出版社推出旗下新子刊Trends in Cancer,作为创刊号的一部分,该杂志邀请世界领先的癌症研究学者,列出了目前癌症研究领域所面临的八大问题。1、对于致癌突变的了解,如何才能指导治疗?科学家们花了几十年时间,来了解可导致细胞分裂失控的精确基因突变。现在癌症患者可以通过自己肿瘤的基因测序,来确定他们疾病的遗传根源,我们已经靶定了其中许多遗传学改变,但我们仍然还没有获得绝大部分

英国启动阿司匹林抗癌症复发试验,预计纳入1.1万人

英国开启世界上最大规模的临床试验,测试阿司匹林的抗癌效果。 据国外媒体报道,英国将启动世界上最大的临床试验测试阿司匹林的抗癌效果。大约有1.1万曾患有早期肠癌、乳腺癌、前列腺癌、胃癌以及食道癌的人们将参与这项实验。 最近几年,关于阿司匹林是否具有抗癌效果的争论由于其不确定性而越演越烈。科学家称,如果证实这种药物的效果,那么它将带来革命性变化,为癌症患者提供一种廉价而有效的治疗方

Lancet Oncol:高收入国家,本地居民患癌率与非本地居民不同

背景在高收入国家,本土居民相比非本土居民而言,往往身体素质更差,预期寿命更短暂。在澳大利亚、新西兰、加拿大和美国等国家,我们尚不清楚本地居民的癌症发病率及死亡率数据。此项研究旨在首次调查和比较在这些国家的本土人群的患癌率。 方式研究人员在澳大利亚的三个地区(昆士兰、西澳大利亚州、北领地)、新西兰,加拿大阿尔伯塔省和美国的卫生服务领域等地的肿瘤注册信息采集了人们罹患癌症的发生率。阿尔伯塔省第一民族和

J Thromb Haemost:癌症并发静脉血栓应用阿哌沙班治疗

J Thromb Haemost:癌症并发静脉血栓应用阿哌沙班治疗背景:AMPLIFY试验比较应用阿哌沙班和依诺肝素/华法林治疗急性静脉栓塞(VTE)。目的:亚组分析比较阿哌沙班和依诺肝素/华法林治疗癌症存在VTE的有效性和安全性。方法:症状性VTE患者随机分为阿哌沙班或依诺肝素/华法林治疗。主要效果预后以及安全预后分别为:VTE复发或VTE相关死亡以及严重出血。结果:共有5395名患者,其中16

JAMA Oncol:癌症患者重症监护——时间多长更合适?

 就美国而言,五分之一的死亡发生在重症监护室。尽管仍不清楚更高级别的重症监护是否可以带来更好的结果,但是很难去判定病人最终是否从重症监护获益。目前被送进ICU的病人中有超过15%的是被诊断为癌症,但是恶性肿瘤的诊断是和医生的悲观有关系的。向病人提供有时间限制的重症监护是很常见的,尤其是针对恶性肿瘤患者。但是,目前鲜有证据来指导ICU监护的时间。 由此可见,确定癌症重症患者的重症

Baidu
map
Baidu
map
Baidu
map